FORXIGA 10MG TABLETS: Advanced SGLT2 Inhibitor Therapy for Diabetes Management
FORXIGA 10MG TABLETS contain Dapagliflozin 10mg, an oral antidiabetic medicine belonging to the Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor class. It is prescribed for improving blood glucose control in adults with type 2 diabetes mellitus and may also be used in selected patients with heart failure or chronic kidney disease according to medical evaluation.
Dapagliflozin works by helping the kidneys remove excess glucose through urine, thereby reducing blood glucose levels through an insulin-independent mechanism. FORXIGA 10MG TABLETS are prescription-only medicines and should be used under the supervision of a qualified healthcare professional.
Key Benefits of FORXIGA 10MG TABLET
Helps improve blood sugar control in adults with type 2 diabetes.
Promotes elimination of excess glucose through urine.
Works without directly increasing insulin production.
May support heart health in eligible patients with heart failure.
May provide kidney-related benefits in suitable chronic kidney disease patients.
Can be used alone or with other diabetes medicines as prescribed.
How FORXIGA 10MG TABLETS Works
FORXIGA contains Dapagliflozin, which blocks the action of the SGLT2 transporter in the kidneys.
Normally, SGLT2 helps reabsorb filtered glucose back into the bloodstream. By inhibiting this transporter, Dapagliflozin reduces glucose reabsorption and allows excess glucose to be removed through urine.
This mechanism helps lower blood glucose levels and provides additional metabolic effects without depending on insulin secretion.
Usage Instructions for FORXIGA 10MG TABLETS
Swallow the tablet whole with water.
It may be taken with or without food.
Take it at the same time each day for consistent results.
Regular monitoring of blood glucose and kidney function may be required.
Medicinal Advantages of FORXIGA 10MG TABLETS
Supports better glycemic control in type 2 diabetes.
Helps reduce excess glucose levels through urinary glucose removal.
Provides an oral treatment option for long-term diabetes management.
May reduce the risk of hospitalization due to heart failure in appropriate patients.
Supports kidney health management in selected chronic kidney disease patients.
Off-Label Uses of FORXIGA 10MG TABLETS
Dapagliflozin may be evaluated by specialists for additional medical applications based on clinical evidence and individual patient requirements.
Individualized metabolic disease management.
Additional cardiovascular or kidney-related treatment approaches.
Expert Advice for Optimal Use
Maintain adequate hydration unless your doctor advises fluid restriction.
Monitor blood sugar levels regularly.
Maintain proper hygiene to reduce infection risks.
Precautions
Kidney Function
Kidney function should be evaluated before and during treatment because Dapagliflozin acts through the kidneys. Dose suitability depends on kidney function and medical condition.
Blood Sugar Monitoring
When combined with insulin or insulin-releasing medicines, the risk of low blood sugar may increase. Dose adjustment may be required.
Pregnancy & Breastfeeding
Consult your healthcare provider before using FORXIGA during pregnancy or breastfeeding.
Storage Instructions
Store at room temperature as directed on the pack.
Keep tablets in the original blister packaging.
Protect from moisture and direct sunlight.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is FORXIGA 10MG TABLETS used for?
A: FORXIGA 10MG TABLETS are used for managing type 2 diabetes mellitus and may also be prescribed for certain heart failure and chronic kidney disease indications in suitable patients.
Q: What is the active ingredient in FORXIGA 10MG?
A: The active ingredient is Dapagliflozin 10mg, an SGLT2 inhibitor medicine.
Q: Is FORXIGA 10MG an insulin medicine?
A: No. FORXIGA does not contain insulin. It works by increasing glucose removal through the kidneys.
Q: Does FORXIGA 10MG help with kidney health?
A: Dapagliflozin may help reduce the risk of kidney disease progression in eligible chronic kidney disease patients when prescribed according to approved indications.
